Inhibition of mTOR activation reduces proteinuria and glomerulosclerosis (Miesen et al., 2020), but complete reduction in mTOR activity may lead to glomerular disease progression (Letavernier et al., 2007; Cai et al., 2011), indicating that the therapeutic window of the drug is narrow. Here, MTOR is linked to glomerulosclerosis.